Management of rheumatoid arthritis: the 2012 perspective

References

• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16(2):75–6.
   PubMedGoogle Scholar
• Yamanaka H. A cohort study of clinical care in rheumatoid arthritis: the IORRA study. JMAJ. 2009;52(1):54–6.
   Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheuma-toid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4): 283–9.
   PubMedGoogle Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, American College of Rheumatology; European League Against Rheumatism, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 201 1 ;63(3):573–86.
   Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheu-matoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3): 404–13.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17(2):98–105.
   PubMedGoogle Scholar
• Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, Momohara S, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011;21(6):579–93.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheuma-toid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39(5):360–7.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Davis JM 3rd, Crowson CS, Gabriel SE. Epide-miology of rheumatoid arthritis: rheumatoid arthritis and mor-tality. Curr Rheumatol Rep. 2010;12(5):379–85.
   Google Scholar
• Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmaco-economics. 2010;28(6):477–87.
   Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the man-agement of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010; 69(6) : 964–75.
   PubMed Web of Science ®Google Scholar
• Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5): 625–39.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, et al. 2010 Rheu-matoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collabo-rative initiative. Ann Rheum Dis. 2010;69(9):1580–8.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67(8):1153–8.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, T2T Expert Committee, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
   Google Scholar
• Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schir-mer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheu-matism/American College of Rheumatology collaborative initia-tive. Arthritis Rheum. 2012;64(4):943–54.
   Google Scholar
• Fukae J, Kon Y, Henmi M, Sakamoto F, Narita A, Shimizu M, et al. Change of synovial vascularity in a single finger joint assessed by power Doppler sonography correlated with radio-graphic change in rheumatoid arthritis: comparative study of a novel quantitative score with a semiquantitative score. Arthritis Care Res (Hoboken). 2010;62(5):657–63.
   PubMed Web of Science ®Google Scholar
• Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66(11):1473–8.
   Google Scholar
• Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nord-strom DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.
   Google Scholar
• Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;(7):CD008331.
   Google Scholar
• Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011;25(13 Suppl 1):55.
   Google Scholar
• Buch MH, Emery P. New therapies in the management of rheu-matoid arthritis. Curr Opin Rheumatol. 2011;23(3):245–51.
   PubMed Web of Science ®Google Scholar
• G6mez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007;57(5): 756–61.
   PubMed Web of Science ®Google Scholar
• Harigai M, Koike R, Miyasaka N, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357(18):1874–6.
   Google Scholar
• Tanaka E, Inoue E, Hoshi D, Nakajima A, Momohara S, Taniguchi A, et al. Analysis of medical cost for care of rheu-matoid arthritis patients before and after usage of the biologics using a large cohort database, IORRA (abstract). Mod Rheuma-tol. 2009;19(Suppl):S46.
   Google Scholar
• Gu N, Yi S, Kim TE, Kim J, Shin SG, Jong IJ, et al. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin 'Ther. 2011;33(12):2029–37.
   PubMed Web of Science ®Google Scholar
• Fleischmann R. Novel small-molecular therapeutics for rheuma-toid arthritis. Curr Opin Rheumatol. 2012 (Epub ahead of print).
   Google Scholar
• Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis-the kinase inhibitors. Bull NYU Hosp Jt Dis. 2011; 69(3):233–7.
   PubMedGoogle Scholar
• Okamoto H, Kobayashi A. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2011;364(1):83–4.
   PubMedGoogle Scholar
• Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107(1): 176–83.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in com-bination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 2012;64(4):970–81.
   Google Scholar
• Furst DE. Observational cohort studies and well controlled clin-ical trials-we need them both! J Rheumatol. 2004;31(8):1476–7.
   Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, CORRONA Investigators, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–82.
   PubMed Web of Science ®Google Scholar
• Camacho EM, Lunt M, Farragher TM, Verstappen SM, Bunn DK, Symmons DP. The relationship between oral contraceptive use and functional outcome in women with recent-onset inflam-matory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum. 2011;63(8):2183–91.
   PubMed Web of Science ®Google Scholar
• Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coro-nary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2012;64(1):42–52.
   Google Scholar
• Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76(6):653–6.
   PubMed Web of Science ®Google Scholar
• Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmèn M, et al. Outcomes from the patient perspective workshop at OMERACT 6. J Rheumatol. 2003;30(4):868–72.
   Google Scholar
• van Tuyl LH, Smolen JS, Wells GA, Scholte-Voshaar M, Hoogland W, Boers M. Patient perspective on remission in rheumatoid arthritis. J Rheumatol. 2011;38(8):1735–8.
   Google Scholar
• de Wit MP, Smolen JS, Gossec L, van der Heijde DM. Treating rheumatoid arthritis to target: the patient version of the interna-tional recommendations. Ann Rheum Dis. 2011;70(6):891–5.
   Google Scholar
• Hood L. A personal journey of discovery: developing technology and changing biology. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:1–43.
   PubMed Web of Science ®Google Scholar
• Hood L, Friend SH. Predictive, personalized, preventive, partic-ipatory (P4) cancer medicine. Nature Rev Clin Oncol. 2011;8: 184–7.
   PubMed Web of Science ®Google Scholar
• Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet. 2012;25;44(5): 511–6.
   Google Scholar
• Terao C, Ohmura K, Kochi Y, Ikari K, Maruya E, Katayama M, et al. A large-scale association study identified multiple HLA-DRB1 alleles associated with ACPA-negative rheumatoid arthritis in Japanese subjects. Ann Rheum Dis. 2011;70(12): 2134–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto K, Ikari K, Kaneko H, Tsukahara S, Kochi Y, Yamamoto K, et al. Association of EMCN with susceptibility to rheumatoid arthritis in a Japanese population. J Rheumatol. 2011;38(2):221–8.
   PubMed Web of Science ®Google Scholar
• Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet. 2010;42(6):515–9.
   PubMed Web of Science ®Google Scholar
• Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, et al. The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 2010;62(2):574–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto K, Kochi Y, Ikari K, Yamamoto K, Suzuki A, Shimane K, et al. Association study of TRAF1-05 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythe-matosus in Japanese. Ann Rheum Dis. 2010;69(2):368–73.
   PubMed Web of Science ®Google Scholar
• Carton J. The extreme future. London: A Plume Book; 2007.
   Google Scholar